-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|November 12, 2020

US Oncology Network Enrolls 100,000th Patient in the OCM

The US Oncology Network reached a major milestone recently in its journey to provide high-quality, value-based care to local communities by enrolling its 100,000th patient in the Centers for Medicare & Medicaid Innovation’s (CMMI) Oncology Care Model (OCM)

THE WOODLANDS, TEXAS, Nov. 11, 2020—The US Oncology Network reached a major milestone recently in its journey to provide high-quality, value-based care to local communities by enrolling its 100,000th patient in the Centers for Medicare & Medicaid Innovation’s (CMMI) Oncology Care Model (OCM). In realizing this goal, the participating Network practices delivered more than $122 million in cumulative savings to Medicare over the program’s first six performance periods (PP).

The OCM is a 5-year pilot program developed by CMMI to provide higher quality, more coordinated cancer care at the same or lower cost to Medicare. The program is part of Medicare’s ongoing effort to move healthcare to a system based on value rather than volume.

The OCM is a very large, complex program that requires enhanced patient care, effective cost management and comprehensive clinical data reporting to Medicare, to highlight only a few key elements of the program. Practices across The Network are performing well in the OCM, and most have shown improvement for each subsequent performance period.

The Network, supported by McKesson, also provides practices access to thought leaders and key staff who have deep expertise in the OCM and value-based care.

Read the full press release.​


Related to this article

Anthony Stein, MD | Image: City of Hope
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.